|
|
BTGN Detection Assay (200 rxns)
US & Canada List Price: $552.90
The Bile Tolerant Gram Negative (BTGN) Detection Assay is used to detect species of bacteria that can survive in the human stomach and are potentially harmful to humans. The species covered in our PathoSEEK® Total Enterobacteriaceae assay and the PathoSEEK® Pseudomonas aeruginosa assay sufficiently cover the species identified as BTGN. For ease of use, we multiplexed theses assays so they can both be tested in one well.
Important note concerning one component of this assay: The Pseudomonas aeruginosa assay has been shown (via Sanger sequencing of the amplicons) to amplify Pseudomonas rhizosphaerae, an off-target species. P. rhizosphaerae has been found on some hemp plants in Canada. We have designed our Pseudomonas assay to target closely-related P. aeruginosa strains that are pathogenic to humans and listed in the Cystic Fibrosis literature. The exclusion criteria for these primers did not include microbes that are not available in tissue banks, such as P. rhizosphaerae. The health risks of beneficial microbes still need to be scrutinized for agricultural products that are inhaled. To date, we are not aware of any clinical reports of harm from P. rhizosphaerae.
P. rhizosphaerae is not commercially available from ATCC (American Type Culture Collection) for purchase and identification, thus it is difficult to ascertain if it forms colonies and to what extent this species is inflating the CFU/g estimates from the P. aeruginosa assay. We are actively investigating primers that exclude this beneficial microbe and are open to collaboration with laboratories that have specific experience culturing and quantifying this microbe.
The Bile Tolerant Gram Negative (BTGN) Detection Assay is used to detect species of bacteria that can survive in the human stomach and are potentially harmful to humans. The species covered in our PathoSEEK® Total Enterobacteriaceae assay and the PathoSEEK® Pseudomonas aeruginosa assay sufficiently cover the species identified as BTGN. For ease of use, we multiplexed theses assays so they can both be tested in one well.
Important note concerning one component of this assay: The Pseudomonas aeruginosa assay has been shown (via Sanger sequencing of the amplicons) to amplify Pseudomonas rhizosphaerae, an off-target species. P. rhizosphaerae has been found on some hemp plants in Canada. We have designed our Pseudomonas assay to target closely-related P. aeruginosa strains that are pathogenic to humans and listed in the Cystic Fibrosis literature. The exclusion criteria for these primers did not include microbes that are not available in tissue banks, such as P. rhizosphaerae. The health risks of beneficial microbes still need to be scrutinized for agricultural products that are inhaled. To date, we are not aware of any clinical reports of harm from P. rhizosphaerae.
P. rhizosphaerae is not commercially available from ATCC (American Type Culture Collection) for purchase and identification, thus it is difficult to ascertain if it forms colonies and to what extent this species is inflating the CFU/g estimates from the P. aeruginosa assay. We are actively investigating primers that exclude this beneficial microbe and are open to collaboration with laboratories that have specific experience culturing and quantifying this microbe.
All Medicinal Genomics reagents are manufactured in a facility certified to ISO 9001 standards. All lots of reagents are functionally tested in house and Certificates of Analysis (COAs) are available upon request.
Please contact support@medicinalgenomics.com if you have any questions or concerns.
|
|
|
|
